Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS

Ilaris (canakinumab) - Novartis

emavusertib (CA-4948) - Curis, Dr. Reddy’s

IRAK4 inhibitor - Merck (MSD)

https://ash.confex.com/ash/2024/webprogram/Paper199032.html

Anne Sophie Kubasch, MD1; Katharina Zoldan, Dr.1; Michael Cross, Dr.1; Marie Schneider1; Jens Przybilla2; Dirk Hasenclever, PhD2,3; Klaus H Metzeler, MD1; Uwe Platzbecker, MD1

Nov 6, 2024